Gurnet Point Capital, the $2 billion health care and life science investment firm that recruited former Sanofi CEO Christopher Viehbacher earlier this year, has committed $600 million to one of Viehbacher's pet projects: a company called Boston Pharmaceuticals Inc. that will bridge the valley of death between promising early-stage drugs and big pharma's aversion to R&D risk. [See Deal]
"We can green up that valley of death," Viehbacher said in an interview with Scrip. Boston Pharmaceuticals was established with enough capital to scour thousands of Phase-I ready programs and build a portfolio of 20 to 25 Phase I and II drug candidates that the company will attempt to de-risk then sell or license to interested partners
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
